Debt-to-equity of Mersana Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Mersana Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 30 Sep 2025.
  • Mersana Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -364%, a 139% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Mersana Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -364% -1304% -139% 30 Sep 2025
Q2 2025 -653% -1243% -211% 30 Jun 2025
Q1 2025 -2060% -2443% -639% 31 Mar 2025
Q4 2024 2375% +2024% +577% 31 Dec 2024
Q3 2024 940% +636% +209% 30 Sep 2024
Q2 2024 590% +317% +116% 30 Jun 2024
Q1 2024 383% +168% +78% 31 Mar 2024
Q4 2023 351% +197% +128% 31 Dec 2023
Q3 2023 304% +192% +171% 30 Sep 2023
Q2 2023 274% +204% +295% 30 Jun 2023
Q1 2023 215% +162% +309% 31 Mar 2023
Q4 2022 154% +116% +305% 31 Dec 2022
Q3 2022 112% +84% +304% 30 Sep 2022
Q2 2022 69% +48% +219% 30 Jun 2022
Q1 2022 53% +35% +196% 31 Mar 2022
Q4 2021 38% +19% +104% 31 Dec 2021
Q3 2021 28% +7% +37% 30 Sep 2021
Q2 2021 22% -3% -13% 30 Jun 2021
Q1 2021 18% -18% -50% 31 Mar 2021
Q4 2020 19% -10% -34% 31 Dec 2020
Q3 2020 20% -26% -56% 30 Sep 2020
Q2 2020 25% -45% -64% 30 Jun 2020
Q1 2020 35% 31 Mar 2020
Q4 2019 28% 31 Dec 2019
Q3 2019 46% 30 Sep 2019
Q2 2019 70% 30 Jun 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.